$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2016 Form 10-K Financial Statement

#000162828016017936 Filed on July 29, 2016

Income Statement

Concept	2016	2015 Q2	2015
Revenue	$11.18M	$3.240M	$8.863M
YoY Change	26.16%	31.71%	-23.26%
Cost Of Revenue	$8.690M	$2.220M	$7.630M
YoY Change	13.89%	133.68%	111.94%
Gross Profit	$2.500M	$1.020M	$1.230M
YoY Change	103.25%	-32.45%	-84.53%
Gross Profit Margin	22.36%	31.48%	13.88%
Selling, General & Admin	$8.618M	$2.340M	$9.623M
YoY Change	-10.44%	-27.78%	3.67%
% of Gross Profit	344.72%	229.41%	782.36%
Research & Development	$4.194M	$1.090M	$4.845M
YoY Change	-13.44%	67.69%	113.91%
% of Gross Profit	167.76%	106.86%	393.9%
Depreciation & Amortization	$156.0K	$40.00K	$214.0K
YoY Change	-27.1%	-20.0%	0.47%
% of Gross Profit	6.24%	3.92%	17.4%
Operating Expenses	$21.50M	$3.430M	$22.10M
YoY Change	-2.73%	-11.83%	24.09%
Operating Profit	-$10.32M	-$2.410M	-$13.24M
YoY Change	-22.07%	1.26%	111.47%
Interest Expense	$0.00	-$1.010M	$400.0K
YoY Change	-100.0%	-520.83%	-141.24%
% of Operating Profit
Other Income/Expense, Net	-$38.00K	-$170.0K	$225.0K
YoY Change	-116.89%	30.77%	-119.93%
Pretax Income	-$10.35M	-$3.580M	-$13.01M
YoY Change	-20.43%	57.71%	76.11%
Income Tax	$92.00K	$100.0K	$127.0K
% Of Pretax Income
Net Earnings	-$10.45M	-$3.680M	-$13.14M
YoY Change	-20.51%	62.11%	77.42%
Net Earnings / Revenue	-93.41%	-113.58%	-148.26%
Basic Earnings Per Share	-$1.20		-$2.20
Diluted Earnings Per Share	-$1.20	-$509.7K	-$2.20
COMMON SHARES
Basic Shares Outstanding	8.695M shares		5.985M shares
Diluted Shares Outstanding	8.695M shares		6.424M shares

Balance Sheet

Concept	2016	2015 Q2	2015
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.590M	$9.360M	$9.360M
YoY Change	-72.33%	58.91%	58.91%
Cash & Equivalents	$2.590M	$9.357M	$9.360M
Short-Term Investments
Other Short-Term Assets	$440.0K	$350.0K	$350.0K
YoY Change	25.71%	-7.89%	-7.89%
Inventory
Prepaid Expenses
Receivables	$1.310M	$1.060M	$1.060M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.340M	$10.76M	$10.76M
YoY Change	-59.67%	41.64%	41.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$620.0K	$452.0K	$450.0K
YoY Change	37.78%	4.15%	4.65%
Goodwill		$669.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.0K	$160.0K	$160.0K
YoY Change	-6.25%	-5.88%	-5.88%
Total Long-Term Assets	$1.440M	$1.284M	$1.290M
YoY Change	11.63%	1.26%	1.57%
TOTAL ASSETS
Total Short-Term Assets	$4.340M	$10.76M	$10.76M
Total Long-Term Assets	$1.440M	$1.284M	$1.290M
Total Assets	$5.780M	$12.05M	$12.05M
YoY Change	-52.03%	35.86%	35.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.900M	$1.414M	$1.410M
YoY Change	34.75%	44.14%	43.88%
Accrued Expenses	$270.0K	$373.0K	$370.0K
YoY Change	-27.03%	-36.46%	-37.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.310M	$3.796M	$3.800M
YoY Change	39.74%	3.74%	3.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$230.0K	$192.0K	$190.0K
YoY Change	21.05%		-90.55%
Total Long-Term Liabilities	$230.0K	$192.0K	$190.0K
YoY Change	21.05%		-90.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.310M	$3.796M	$3.800M
Total Long-Term Liabilities	$230.0K	$192.0K	$190.0K
Total Liabilities	$5.540M	$3.988M	$3.990M
YoY Change	38.85%	-29.66%	-29.63%
SHAREHOLDERS EQUITY
Retained Earnings		-$52.02M
YoY Change		33.8%
Common Stock		$61.33M
YoY Change		41.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$1.252M
YoY Change		0.0%
Treasury Stock Shares		269.7K shares
Shareholders Equity	$240.0K	$8.059M	$8.060M
YoY Change
Total Liabilities & Shareholders Equity	$5.780M	$12.05M	$12.05M
YoY Change	-52.03%	35.86%	35.85%

Cashflow Statement

Concept	2016	2015 Q2	2015
OPERATING ACTIVITIES
Net Income	-$10.45M	-$3.680M	-$13.14M
YoY Change	-20.51%	62.11%	77.42%
Depreciation, Depletion And Amortization	$156.0K	$40.00K	$214.0K
YoY Change	-27.1%	-20.0%	0.47%
Cash From Operating Activities	-$6.408M	-$2.010M	-$9.630M
YoY Change	-33.46%	-1646.15%	180.76%
INVESTING ACTIVITIES
Capital Expenditures	$322.0K	-$40.00K	$119.0K
YoY Change	170.59%	-42.86%	-49.15%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K	$10.00K
YoY Change	-100.0%
Cash From Investing Activities	-$322.0K	-$30.00K	-$114.0K
YoY Change	182.46%	-57.14%	-50.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$42.00K	11.21M	$13.21M
YoY Change	-100.32%	55950.0%	65950.0%
NET CHANGE
Cash From Operating Activities	-$6.408M	-2.010M	-$9.630M
Cash From Investing Activities	-$322.0K	-30.00K	-$114.0K
Cash From Financing Activities	-$42.00K	11.21M	$13.21M
Net Change In Cash	-$6.772M	9.170M	$3.466M
YoY Change	-295.38%	11362.5%	-195.22%
FREE CASH FLOW
Cash From Operating Activities	-$6.408M	-$2.010M	-$9.630M
Capital Expenditures	$322.0K	-$40.00K	$119.0K
Free Cash Flow	-$6.730M	-$1.970M	-$9.749M
YoY Change	-30.97%	-1085.0%	166.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	csbr	Additional Stock Option Plan Expense AdditionalStockOptionPlanExpense	386578	USD
CY2015	csbr	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	214000	USD
CY2016	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	2102000	USD
CY2014Q4	csbr	Capital Leases Monthly Payments CapitalLeasesMonthlyPayments	3000	USD
CY2015Q1	csbr	Classof Warrantor Right Numberof Securities Calledby Each Warrantor Right Percent ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRightPercent	0.0055
CY2016	csbr	Classof Warrantor Right Termof Warrant ClassofWarrantorRightTermofWarrant	P5Y
CY2015	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	2733000	USD
CY2015	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	4900000	USD
CY2016	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	6584000	USD
CY2015	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	-0.008
CY2016	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	-0.006
CY2015	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.009
CY2016	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.002
CY2015Q1	csbr	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	1600000	USD
CY2015	csbr	Federal Income Tax Valuation Allowance FederalIncomeTaxValuationAllowance	3912000	USD
CY2016	csbr	Federal Income Tax Valuation Allowance FederalIncomeTaxValuationAllowance	3322000	USD
CY2015	csbr	Foreign Income Tax Valuation Allowance ForeignIncomeTaxValuationAllowance	-8000	USD
CY2016	csbr	Foreign Income Tax Valuation Allowance ForeignIncomeTaxValuationAllowance	-11000	USD
CY2015	csbr	Issuance Cost Of Common Stock IssuanceCostOfCommonStock	880000	USD
CY2016	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	3	subsidiary
CY2015	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	1663000	USD
CY2016	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	1972000	USD
CY2015	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	2000	USD
CY2016	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	0	USD
CY2015	csbr	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	1616000	USD
CY2016	csbr	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0	USD
CY2015Q1	csbr	Repurchase Of Stock In Put Option RepurchaseOfStockInPutOption	4.80
CY2015Q1	csbr	Repurchase Of Stock In Put Option RepurchaseOfStockInPutOption	4.8
CY2015	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P6Y8M12D
CY2016	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P6Y1M6D
CY2015	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	1656073	shares
CY2016	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	0	shares
CY2016	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchanges In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangesInPeriodWeightedAverageExercisePrice	4.92
CY2016	csbr	Share Based Compensation Arrangement By Share Based Payment Award Shares Exchanged In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExchangedInPeriod	1656073	shares
CY2016Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	2109840	shares
CY2015	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	12.48
CY2016	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0.00
CY2015	csbr	State And Local Income Tax Valuation Allowance StateAndLocalIncomeTaxValuationAllowance	287000	USD
CY2016	csbr	State And Local Income Tax Valuation Allowance StateAndLocalIncomeTaxValuationAllowance	537000	USD
CY2015	csbr	Stock Issued During Period Value Conversion Of Convertible Notes And Accrued Interest StockIssuedDuringPeriodValueConversionOfConvertibleNotesAndAccruedInterest	2060000	USD
CY2015	csbr	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	2000	USD
CY2013Q4	csbr	Stock Options Award Shares To Purchase Common Stock StockOptionsAwardSharesToPurchaseCommonStock	16667	shares
CY2013Q4	csbr	Stockholders Equity Reverse Stock Split Conversion Ratio StockholdersEquityReverseStockSplitConversionRatio	0.0833
CY2015	csbr	Translational Oncology Solutions TranslationalOncologySolutions	7200000	USD
CY2016	csbr	Translational Oncology Solutions TranslationalOncologySolutions	9210000	USD
CY2015	csbr	Valuation Allowances ValuationAllowances	4191000	USD
CY2016	csbr	Valuation Allowances ValuationAllowances	3848000	USD
CY2015	csbr	Warrant Modification Charge WarrantModificationCharge	586000	USD
CY2016	csbr	Warrant Modification Charge WarrantModificationCharge	0	USD
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-04-30
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11237176	shares
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q4	dei	Entity Public Float EntityPublicFloat	47500000	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Trading Symbol TradingSymbol	CSBR
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1414000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1896000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1060000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1312000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	373000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	271000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	798000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	954000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	61322000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	63947000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2948000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2599000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	18000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1616000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3162000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2599000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2000	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	32000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4113842	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4322597	shares
CY2015Q2	us-gaap	Assets Assets	12047000	USD
CY2016Q2	us-gaap	Assets Assets	5777000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	10763000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	4340000	USD
CY2015	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	124000	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2016Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	59000	USD
CY2015Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2016Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	92000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	24000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	16000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	27000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	25000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Executory Costs CapitalLeasesFutureMinimumPaymentsExecutoryCosts	149000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	9000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	83000	USD
CY2016Q2	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	24000	USD
CY2015	us-gaap	Capital Leases Income Statement Amortization Expense CapitalLeasesIncomeStatementAmortizationExpense	12405	USD
CY2016	us-gaap	Capital Leases Income Statement Amortization Expense CapitalLeasesIncomeStatementAmortizationExpense	24818	USD
CY2016Q2	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.05
CY2015Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	685000	USD
CY2016Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	715000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5891000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9357000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2585000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3466000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6772000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.76
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8962301	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8974531	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8692616	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8704846	shares
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	124000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	92000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	127000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	92000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3912000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3322000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	8000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	11000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4191000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3848000	USD
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	258000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	67000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2009000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3139000	USD
CY2015	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	724000	USD
CY2016	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2016	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	40000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-287000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-537000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15212000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19071000	USD
CY2015Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	433000	USD
CY2016Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	316000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	0	USD
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	0	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9719000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12970000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	235000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	224000	USD
CY2015Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1000	USD
CY2016Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	12000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4803000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5528000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	21000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	21000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15200000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15212000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19100000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19071000	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	214000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	156000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	214000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	156000	USD
CY2015	us-gaap	Dilutive Securities DilutiveSecurities	-980519	USD
CY2016	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.20
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.20
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.20
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.010
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.308
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.372
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.069
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.022
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.031
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.022
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-13139820	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10446000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5173000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	127000	USD
CY2015	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2016	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2015	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	124000	USD
CY2016	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	92000	USD
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	70000	USD
CY2016Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	73000	USD
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	981000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-5000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5340000	USD
CY2016Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13013000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10354000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	433000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	482000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-265000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	282000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-231000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-102000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-82000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1130000	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	100000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	65000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	97000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-2000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	439065	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	222000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	304000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	3988000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	5539000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12047000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5777000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3796000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5306000	USD
CY2016Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	165000	USD
CY2015Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	493000	USD
CY2016Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	782000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13210000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-322000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9630000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6452000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-13140000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10445537	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10445537	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	225000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	248904000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38000	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	22101000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	21498000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-13238000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-10316000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	319911000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14120339	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	71007000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	192000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	233000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-170000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	880000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	18000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	119000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	322000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	346000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	443000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	44000	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	11220000	USD
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2015	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5000	USD
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1250000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1572000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	452000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	618000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	30000	USD
CY2015	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	12000	USD
CY2016	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	24000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4845000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4194000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	163000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52020000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62466000	USD
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	8863000	USD
CY2016	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	11182000	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4283000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.02
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.93
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.86
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.83
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3445000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3162000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2599000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1425923	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1737306	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.88
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.71
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	36309	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	92479	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12604	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	42515	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1763381	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	343749	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.32
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.54
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	985000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4166000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1945920	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2004002	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2212757	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.12
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.74
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.58
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4166000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2004002	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2212757	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1468161	shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.88
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.88
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.97
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.52
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.90
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.92
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	11160000	USD
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.33
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2879000	USD
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2015	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	3000	USD
CY2016	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	313	shares
CY2016	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	44000	USD
CY2016	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	213951	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	3197000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	8059000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	238000	USD
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2015Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	636000	USD
CY2016Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	617000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	165000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	79000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	23000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	21000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	42000	USD
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6424411	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8695199	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5985346	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8695199	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5985346	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8695199	shares
CY2016	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue represents payments received in advance for products to be delivered.  When products are delivered, deferred revenue is then recognized as earned.</font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-017936-index-headers.html	Edgar Link	pending
0001628280-16-017936-index.html	Edgar Link	pending
0001628280-16-017936.txt	Edgar Link	pending
0001628280-16-017936-xbrl.zip	Edgar Link	pending
csbr-20160430.xml	Edgar Link	completed
csbr-20160430.xsd	Edgar Link	pending
csbr-20160430_cal.xml	Edgar Link	unprocessable
csbr-20160430_def.xml	Edgar Link	unprocessable
csbr-20160430_lab.xml	Edgar Link	unprocessable
csbr-20160430_pre.xml	Edgar Link	unprocessable
csbr10-k4302016.htm	Edgar Link	pending
csbrex21.htm	Edgar Link	pending
csbrex231.htm	Edgar Link	pending
csbrex311.htm	Edgar Link	pending
csbrex312.htm	Edgar Link	pending
csbrex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2016 Form 10-K Financial Statement

#000162828016017936 Filed on July 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2016 Form 10-K Financial Statement

#000162828016017936 Filed on July 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr